Prelude Capital Management, LLC Cytokinetics Inc Transaction History
Prelude Capital Management, LLC
- $1.57 Billion
- Q3 2024
A detailed history of Prelude Capital Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Prelude Capital Management, LLC holds 18,891 shares of CYTK stock, worth $919,047. This represents 0.06% of its overall portfolio holdings.
Number of Shares
18,891
Previous 18,891
-0.0%
Holding current value
$919,047
Previous $997,000
-0.0%
% of portfolio
0.06%
Previous 0.04%
Shares
17 transactions
Others Institutions Holding CYTK
# of Institutions
404Shares Held
124MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$714 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$572 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$471 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$378 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$314 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.58B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...